Language:

Erythropoietin Both Protects from and Reverses Experimental Diabetic Neuropathy

Proceedings of the National Academy of Sciences - PNAS, 2004-01, Vol.101 (3), p.823-828 [Peer Reviewed Journal]

Copyright 1993-2004 National Academy of Sciences of the United States of America ;Copyright © 2004, The National Academy of Sciences 2004 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.0307823100 ;PMID: 14718663

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Erythropoietin Both Protects from and Reverses Experimental Diabetic Neuropathy
Author: Bianchi, Roberto ; Buyukakilli, Belgin ; Brines, Michael ; Savino, Costanza ; Cavaletti, Guido ; Oggioni, Norberto ; Lauria, Giuseppe ; Borgna, Monica ; Lombardi, Raffaella ; Cimen, Burak ; Comelekoglu, Ulku ; Kanik, Arzu ; Tataroglu, Cengiz ; Cerami, Anthony ; Ghezzi, Pietro
Subjects: Animals ; Biological Sciences ; Bone marrow ; Diabetes ; Diabetes complications ; Diabetes mellitus ; Diabetes Mellitus, Experimental - drug therapy ; Diabetic neuropathies ; Diabetic Neuropathies - drug therapy ; Diabetic Neuropathies - physiopathology ; Diabetic Neuropathies - prevention & control ; Electrophysiology ; Epics ; Erythropoietin - therapeutic use ; Humans ; Leukemia ; Male ; Medical treatment ; Nerve Fibers - drug effects ; Nerve Fibers - pathology ; Nerves ; Nervous system ; Neurology ; Nociceptors - drug effects ; Nociceptors - physiopathology ; Physical trauma ; Rats ; Rats, Sprague-Dawley ; Rats, Wistar ; Recombinant Proteins ; Sciatic nerve ; Sodium-Potassium-Exchanging ATPase - metabolism
Is Part Of: Proceedings of the National Academy of Sciences - PNAS, 2004-01, Vol.101 (3), p.823-828
Description: Erythropoietin (EPO) possesses generalized neuroprotective and neurotrophic actions. We tested the efficacy of recombinant human EPO (rhEPO) in preventing and reversing nerve dysfunction in streptozotocin (STZ)-induced diabetes in rats. Two days after STZ [60 mg/kg of body weight (b.w.), i.p.], diabetic animals were administered rhEPO ($40\>\mu g/kg$of b.w.) three times weekly for 5 weeks either immediately (preventive) before or after a 5-week delay (therapeutic) after induction of hyperglycemia or at a lower dose ($8\>\mu g/kg$of b.w. once per week) for 8 weeks (prolonged). Tail-nerve conduction velocities (NCV) was assessed at 5 and 11 weeks for the preventive and therapeutic schedule, respectively. Compared to nondiabetic rats, NCV was 20% lower after 5 weeks in the STZ group, and this decrease was attenuated 50% by rhEPO. Furthermore, the reduction of Na+,K+-ATPase activity of diabetic nerves (by 55%) was limited to 24% in the rhEPO-treated group. In the therapeutic schedule, NCV was reduced by 50% after 11 weeks but by only 23% in the rhEPO-treated group. rhEPO treatment attenuated the decrease in compound muscle action potential in diabetic rats. In addition, rhEPO treatment was associated with a preservation of footpad cutaneous innervation, as assessed by protein gene product 9.5 immunostaining. Diabetic rats developed alterations in mechanical and thermal nociception, which were partially reversed by rhEPO given either in a preventative or therapeutic manner. These observations suggest that administration of rhEPO or its analogues may be useful in the treatment of diabetic neuropathy.
Publisher: United States: National Academy of Sciences
Language: English
Identifier: ISSN: 0027-8424
EISSN: 1091-6490
DOI: 10.1073/pnas.0307823100
PMID: 14718663
Source: GFMER Free Medical Journals
MEDLINE
PubMed Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Erythropoietin Both Protects from and Reverses Experimental Diabetic Neuropathy

Copyright 1993-2004 National Academy of Sciences of the United States of America ;Copyright © 2004, The National Academy of Sciences 2004 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.0307823100 ;PMID: 14718663

Searching Remote Databases, Please Wait